Ignite Creation Date:
2025-12-25 @ 1:10 AM
Ignite Modification Date:
2025-12-25 @ 11:21 PM
Study NCT ID:
NCT00358293
Status:
COMPLETED
Last Update Posted:
2009-01-21
First Post:
2006-07-27
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Sponsor:
Teva GTC
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
Protocol C2/5/TZ-MS-05
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None